The effect of renin-angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia

Ju Hyun Lee, Young Eun Kwon, Jung Tak Park, Mi Jung Lee, Hyung Jung Oh, Seung Hyeok Han, Shin Wook Kang, Kyu Hun Choi, Tae Hyun Yoo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hypothesis: The aim of this study was to determine the effects of renin-angiotensin system (RAS) blockade maintenance on renal protection in chronic kidney disease (CKD) patients with hyperkalemia occurring during treatment with RAS blockade. Materials and methods: CKD III or IV patients, who were prescribed with RAS blockers and also had hyperkalemia, were included. The study population was divided into two groups based on maintenance or withdrawal of RAS blocker. Renal outcomes (doubling of creatinine or end-stage renal disease) and incidence of hyperkalemia were compared between the two groups. Results: Out of 258 subjects who developed hyperkalemia during treatment with RAS blockers, 150 (58.1%) patients continued on RAS blockades, while RAS blockades were discontinued for more than 3 months in the remaining 108 patients. Renal event-free survival was significantly higher in the maintenance group compared with the withdrawal group. Cox proportional hazard ratio for renal outcomes was 1.35 (95% CI: 1.08-1.92, p=0.04) in the withdrawal group compared with the maintenance group. However, the incidence of hyperkalemia and hyperkalemia-related hospitalization or mortality did not differ between the two groups. Conclusions:This study demonstrated that the maintenance of RAS blockade is beneficial for the preservation of renal function and relatively tolerable in patients with CKD and hyperkalemia occurring during treatment with RAS blockade.

Original languageEnglish
Pages (from-to)491-497
Number of pages7
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Volume15
Issue number4
DOIs
Publication statusPublished - 2014 Dec 17

Fingerprint

Hyperkalemia
Renin-Angiotensin System
Chronic Renal Insufficiency
Kidney
Maintenance
Incidence
Disease-Free Survival
Chronic Kidney Failure
Creatinine
Hospitalization
Therapeutics
Mortality

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology

Cite this

@article{83f542cce28446789cfc209874db3b37,
title = "The effect of renin-angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia",
abstract = "Hypothesis: The aim of this study was to determine the effects of renin-angiotensin system (RAS) blockade maintenance on renal protection in chronic kidney disease (CKD) patients with hyperkalemia occurring during treatment with RAS blockade. Materials and methods: CKD III or IV patients, who were prescribed with RAS blockers and also had hyperkalemia, were included. The study population was divided into two groups based on maintenance or withdrawal of RAS blocker. Renal outcomes (doubling of creatinine or end-stage renal disease) and incidence of hyperkalemia were compared between the two groups. Results: Out of 258 subjects who developed hyperkalemia during treatment with RAS blockers, 150 (58.1{\%}) patients continued on RAS blockades, while RAS blockades were discontinued for more than 3 months in the remaining 108 patients. Renal event-free survival was significantly higher in the maintenance group compared with the withdrawal group. Cox proportional hazard ratio for renal outcomes was 1.35 (95{\%} CI: 1.08-1.92, p=0.04) in the withdrawal group compared with the maintenance group. However, the incidence of hyperkalemia and hyperkalemia-related hospitalization or mortality did not differ between the two groups. Conclusions:This study demonstrated that the maintenance of RAS blockade is beneficial for the preservation of renal function and relatively tolerable in patients with CKD and hyperkalemia occurring during treatment with RAS blockade.",
author = "Lee, {Ju Hyun} and Kwon, {Young Eun} and Park, {Jung Tak} and Lee, {Mi Jung} and Oh, {Hyung Jung} and Han, {Seung Hyeok} and Kang, {Shin Wook} and Choi, {Kyu Hun} and Yoo, {Tae Hyun}",
year = "2014",
month = "12",
day = "17",
doi = "10.1177/1470320313507122",
language = "English",
volume = "15",
pages = "491--497",
journal = "JRAAS - Journal of the Renin-Angiotensin-Aldosterone System",
issn = "1470-3203",
publisher = "SAGE Publications Ltd",
number = "4",

}

The effect of renin-angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia. / Lee, Ju Hyun; Kwon, Young Eun; Park, Jung Tak; Lee, Mi Jung; Oh, Hyung Jung; Han, Seung Hyeok; Kang, Shin Wook; Choi, Kyu Hun; Yoo, Tae Hyun.

In: JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, Vol. 15, No. 4, 17.12.2014, p. 491-497.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of renin-angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia

AU - Lee, Ju Hyun

AU - Kwon, Young Eun

AU - Park, Jung Tak

AU - Lee, Mi Jung

AU - Oh, Hyung Jung

AU - Han, Seung Hyeok

AU - Kang, Shin Wook

AU - Choi, Kyu Hun

AU - Yoo, Tae Hyun

PY - 2014/12/17

Y1 - 2014/12/17

N2 - Hypothesis: The aim of this study was to determine the effects of renin-angiotensin system (RAS) blockade maintenance on renal protection in chronic kidney disease (CKD) patients with hyperkalemia occurring during treatment with RAS blockade. Materials and methods: CKD III or IV patients, who were prescribed with RAS blockers and also had hyperkalemia, were included. The study population was divided into two groups based on maintenance or withdrawal of RAS blocker. Renal outcomes (doubling of creatinine or end-stage renal disease) and incidence of hyperkalemia were compared between the two groups. Results: Out of 258 subjects who developed hyperkalemia during treatment with RAS blockers, 150 (58.1%) patients continued on RAS blockades, while RAS blockades were discontinued for more than 3 months in the remaining 108 patients. Renal event-free survival was significantly higher in the maintenance group compared with the withdrawal group. Cox proportional hazard ratio for renal outcomes was 1.35 (95% CI: 1.08-1.92, p=0.04) in the withdrawal group compared with the maintenance group. However, the incidence of hyperkalemia and hyperkalemia-related hospitalization or mortality did not differ between the two groups. Conclusions:This study demonstrated that the maintenance of RAS blockade is beneficial for the preservation of renal function and relatively tolerable in patients with CKD and hyperkalemia occurring during treatment with RAS blockade.

AB - Hypothesis: The aim of this study was to determine the effects of renin-angiotensin system (RAS) blockade maintenance on renal protection in chronic kidney disease (CKD) patients with hyperkalemia occurring during treatment with RAS blockade. Materials and methods: CKD III or IV patients, who were prescribed with RAS blockers and also had hyperkalemia, were included. The study population was divided into two groups based on maintenance or withdrawal of RAS blocker. Renal outcomes (doubling of creatinine or end-stage renal disease) and incidence of hyperkalemia were compared between the two groups. Results: Out of 258 subjects who developed hyperkalemia during treatment with RAS blockers, 150 (58.1%) patients continued on RAS blockades, while RAS blockades were discontinued for more than 3 months in the remaining 108 patients. Renal event-free survival was significantly higher in the maintenance group compared with the withdrawal group. Cox proportional hazard ratio for renal outcomes was 1.35 (95% CI: 1.08-1.92, p=0.04) in the withdrawal group compared with the maintenance group. However, the incidence of hyperkalemia and hyperkalemia-related hospitalization or mortality did not differ between the two groups. Conclusions:This study demonstrated that the maintenance of RAS blockade is beneficial for the preservation of renal function and relatively tolerable in patients with CKD and hyperkalemia occurring during treatment with RAS blockade.

UR - http://www.scopus.com/inward/record.url?scp=84918554315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918554315&partnerID=8YFLogxK

U2 - 10.1177/1470320313507122

DO - 10.1177/1470320313507122

M3 - Article

C2 - 25143329

AN - SCOPUS:84918554315

VL - 15

SP - 491

EP - 497

JO - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

JF - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

SN - 1470-3203

IS - 4

ER -